<DOC>
	<DOCNO>NCT01299142</DOCNO>
	<brief_summary>The purpose study determine safety tolerability anti-TSG101 human monoclonal antibody ( FGI-101-1A6 ) administer intravenously healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Human Monoclonal Antibody ( FGI-101-1A6 )</brief_title>
	<detailed_description>Primary - - To compare safety profile single intravenous administration FGI-101-1A6 compare Placebo Secondary - To evaluate pharmacokinetics ( PK ) singel intravenous administration FGI-101-1A6 - To evaluate immunogenicity FGI-101-1A6</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy volunteer age 1845 Normal laboratory ( blood test ) result Prior immunization liveattenuated vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>antibody</keyword>
	<keyword>monoclonal</keyword>
	<keyword>virus</keyword>
</DOC>